Skip to main content

Table 1 PET and CT-based response evaluation criteria for immunotherapy

From: Comparative analysis of different response criteria at early phase after PD-1 blockade in non-small lung cancer

18F-FDG PET-based criteria

CT-based criteria

Response

PERCIST

iPERCIST

EORTC

Response

RECIST 1.1

iRECIST

CMR

Complete resolution of 18F-FDG uptake within TLs and disappearance of all other lesions to background

As per PERCIST

As per RECIST 1.1

CR

Disappearance of all TLs and NTLs, all LNs < 10 mm in short-axis diameter

As per RECIST 1.1

PMR

> 30% relative reduction and > 0.8 absolute decrease in SULpeak of hottest lesion

Reduction in sum of SULpeak by at least 30%

After 1 cycle; > 15% of reduction

After ≥2 cycle; > 25% of reduction

PR

> 30% decrease in SOM, no new lesions

As per RECIST 1.1

SMD

Neither CMR, PMR, nor PMD

As per PERCIST

Neither CMR, PMR, nor PMD

SD

Neither CR, PR, nor PD

As per RECIST 1.1

PMD

> 30% relative increase and > 0.8 absolute increase in SULpeak of hottest lesions and unequivocal progression of 18F-FDG uptake NTLs or new 18F-FDG uptake lesion

Unconfirmed PMD of > 30% relative increase needs to be confirmed by > 30% increase at 4 weeks later

> 25% increase of SUV

PD

> 20% increase in SOM of TLs or unequivocal progression of NTLs, or appearance of new lesion

PD by RECIST 1.1 in iUPD needs to be confirmed by follow-up examination of 4-8 weeks

  1. Abbreviations: TLs Target lesions, NTLs Nontarget lesions, SOM Sum of diameter, LN Lymph node, CMR Complete metabolic response, PMR Partial metabolic response, SMD Stable metabolic disease, PMD Progressive metabolic disease, CR Complete response, PR Partial response, SD Stable disease, PD Progressive disease, iUPD Unconfirmed PD